6月4日，据CDE官网消息，长春百克生物科技股份公司联合申请药品“重组带状疱疹疫苗（CHO细胞）”，获得临床试验默示许可，受理号CXSL2500213。
公示信息显示，药品“重组带状疱疹疫苗（CHO细胞）”适应症：接种本品后，可刺激机体产生抗水痘-带状疱疹病毒的免疫力，用于预防带状疱疹。
长春百克生物科技股份公司，成立于2004年，位于长春市，是一家以从事医药制造业为主的企业。企业注册资本41365.7598万人民币，实缴资本36010万人民币。
通过天眼查大数据分析，长春百克生物科技股份公司共对外投资了7家企业，参与招投标项目983次，知识产权方面有商标信息33条，专利信息69条，此外企业还拥有行政许可132个。
主要股东信息显示，长春百克生物科技股份公司由长春高新技术产业（集团）股份有限公司持股46.1538%、长春迪奥科技有限责任公司持股30.7692%、魏学宁持股10%、长春君威生物技术有限公司持股5%、余盛持股5%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.